The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A case series of low-dose sorafenib plus tamoxifen in sorafenib-pretreated patients with advanced hepatocellular carcinoma.
Giovannella Palmieri
No relevant relationships to disclose
Piera Federico
No relevant relationships to disclose
Margaret Ottaviano
No relevant relationships to disclose
Carlo Buonerba
No relevant relationships to disclose
Filomena Calabrese
No relevant relationships to disclose
Pasquale Rescigno
No relevant relationships to disclose
Anapaula De Maio
No relevant relationships to disclose
Mariateresa Micillo
No relevant relationships to disclose
Giuseppe di Lorenzo
No relevant relationships to disclose
Vincenzo Damiano
No relevant relationships to disclose